LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Aldeyra Therapeutics Inc

Fechado

2.65 8.16

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.62

Máximo

2.66

Indicadores-chave

By Trading Economics

Rendimento

5.9M

-9.9M

EPS

-0.17

Margem de lucro

-6,465.066

Funcionários

8

EBITDA

5.9M

-9.4M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+280.82% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-5M

127M

Abertura anterior

-5.51

Fecho anterior

2.65

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Aldeyra Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de abr. de 2025, 22:40 UTC

Grandes Movimentos do Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 de nov. de 2024, 20:20 UTC

Grandes Movimentos do Mercado

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Comparação entre Pares

Variação de preço

Aldeyra Therapeutics Inc Previsão

Preço-alvo

By TipRanks

280.82% parte superior

Previsão para 12 meses

Média 9.33 USD  280.82%

Máximo 11 USD

Mínimo 6 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Aldeyra Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.9 / 2.65Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.